MNPR
Monopar Therapeutics
Key Financials
Operating Income
$-16704415
↓ 3.4%
Net Income
$-13716894
↑ 12.0%
Revenue
$0
NaN%
Total Assets
$140.7M
↑ 133.4%
Shareholders' Equity
$137.8M
↑ 150.4%
Cash & Equivalents
$61.8M
↑ 35.0%
Total Liabilities
$2.9M
↓ 45.0%
Operating Cash Flow
$-12201291.00
↓ 90.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/12/2026 | View on SEC |
| SCHEDULE 13G/A | 8/12/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| 10-Q | 8/12/2026 | View on SEC |
| S-8 POS | 7/22/2026 | View on SEC |
| S-8 POS | 7/22/2026 | View on SEC |
| S-8 POS | 7/22/2026 | View on SEC |
| S-8 POS | 7/22/2026 | View on SEC |
| S-8 | 7/22/2026 | View on SEC |
| 8-K | 7/22/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MNPR |
| Company Name | Monopar Therapeutics |
| CIK | 1645469 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 8473880349 |